These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 25275019

  • 1. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
    Ansari D, Urey C, Hilmersson KS, Bauden MP, Ek F, Olsson R, Andersson R.
    Anticancer Res; 2014 Oct; 34(10):5269-76. PubMed ID: 25275019
    [Abstract] [Full Text] [Related]

  • 2. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N.
    Oncogene; 2013 Mar 28; 32(13):1714-23. PubMed ID: 22580602
    [Abstract] [Full Text] [Related]

  • 3. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
    Mimeault M, Johansson SL, Senapati S, Momi N, Chakraborty S, Batra SK.
    Cancer Lett; 2010 Sep 01; 295(1):69-84. PubMed ID: 20303649
    [Abstract] [Full Text] [Related]

  • 4. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
    Bafna S, Kaur S, Momi N, Batra SK.
    Br J Cancer; 2009 Oct 06; 101(7):1155-61. PubMed ID: 19738614
    [Abstract] [Full Text] [Related]

  • 5. Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma.
    Urey C, Hilmersson KS, Andersson B, Ansari D, Andersson R.
    Anticancer Res; 2017 Nov 06; 37(11):6031-6039. PubMed ID: 29061782
    [Abstract] [Full Text] [Related]

  • 6. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
    Sagar S, Leiphrakpam PD, Thomas D, McAndrews KL, Caffrey TC, Swanson BJ, Clausen H, Wandall HH, Hollingsworth MA, Radhakrishnan P.
    Cancer Lett; 2021 Apr 10; 503():91-102. PubMed ID: 33485947
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
    Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH.
    Cancer Biol Ther; 2015 Apr 10; 16(1):43-51. PubMed ID: 25485960
    [Abstract] [Full Text] [Related]

  • 8. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
    Ahmed AA, Neidle S.
    Molecules; 2020 Nov 19; 25(22):. PubMed ID: 33227941
    [Abstract] [Full Text] [Related]

  • 9. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
    Urey C, Andersson B, Ansari D, Sasor A, Said-Hilmersson K, Nilsson J, Andersson R.
    Scand J Gastroenterol; 2017 May 19; 52(5):595-600. PubMed ID: 28270046
    [Abstract] [Full Text] [Related]

  • 10. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
    Chun SG, Zhou W, Yee NS.
    Cancer Biol Ther; 2009 Jul 19; 8(14):1328-39. PubMed ID: 19421011
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, Pelliccioni S, Schuurhuis GJ, Peters GJ, Giovannetti E.
    Curr Pharm Des; 2013 Jul 19; 19(5):940-50. PubMed ID: 22973962
    [Abstract] [Full Text] [Related]

  • 12. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
    Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, DiGiovanni J, Kiguchi K.
    J Hepatol; 2012 Jul 19; 57(1):84-91. PubMed ID: 22326466
    [Abstract] [Full Text] [Related]

  • 13. In vitro cytotoxicity evaluation of HDAC inhibitor Apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment.
    Bauden M, Tassidis H, Ansari D.
    Toxicol Lett; 2015 Jul 02; 236(1):8-15. PubMed ID: 25917448
    [Abstract] [Full Text] [Related]

  • 14. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
    Lee HS, Park SB, Kim SA, Kwon SK, Cha H, Lee DY, Ro S, Cho JM, Song SY.
    Sci Rep; 2017 Jan 30; 7():41615. PubMed ID: 28134290
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2.
    Dorn DC, Harnack U, Pecher G.
    Anticancer Res; 2004 Jan 30; 24(2B):821-5. PubMed ID: 15161033
    [Abstract] [Full Text] [Related]

  • 16. Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.
    Freeman JW, Wang Y, Giles FJ.
    Cancer Biol Ther; 2009 Jul 30; 8(14):1340-2. PubMed ID: 19440037
    [No Abstract] [Full Text] [Related]

  • 17. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    Wissniowski TT, Meister S, Hahn EG, Kalden JR, Voll R, Ocker M.
    Int J Oncol; 2012 May 30; 40(5):1581-9. PubMed ID: 22266985
    [Abstract] [Full Text] [Related]

  • 18. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N, Vasseur R, Vincent A, Duchêne B, Van Seuningen I, Jonckheere N.
    Oncotarget; 2015 May 10; 6(13):10853-67. PubMed ID: 25890497
    [Abstract] [Full Text] [Related]

  • 19. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
    Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Sugimoto K, Saito Y.
    Int J Clin Oncol; 2011 Dec 10; 16(6):671-8. PubMed ID: 21556798
    [Abstract] [Full Text] [Related]

  • 20. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
    Lu C, Yang D, Sabbatini ME, Colby AH, Grinstaff MW, Oberlies NH, Pearce C, Liu K.
    BMC Cancer; 2018 Feb 06; 18(1):149. PubMed ID: 29409480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.